Interventions for treating oral mucositis for patients with cancer receiving treatment

Worthington, Helen V; Clarkson, Jan E; Eden, OB

doi:10.1002/14651858.cd001973.pub2

Cited by 31 publications

(30 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31,32 Povidone-Iodine (oral) Although earlier trials demonstrated significant reductions in onset, incidence, total duration, and worst grade of oral mucositis with oral povidone-iodine, 9,17,29 a more recent randomized controlled trial (N = 132) did not. Side effects of this agent include tachycardia and palpitations.…”

Section: Pilocarpinementioning

confidence: 99%

Putting Evidence Into Practice®: Evidence-Based Interventions for the Management of Oral Mucositis

Harris¹,

Eilers²,

Harriman³

et al. 2008

Clinical Journal of Oncology Nursing

107

View full text Add to dashboard Cite

Mucositis, an inflammation of the mucous membranes, is a commonly occurring side effect of chemotherapy and radiation. Oral mucositis can cause significant clinical consequences, such as pain, malnutrition, and local and systemic infections. Nurses have a critical role in all aspects of managing mucositis, including assessing it, teaching oral care, administering pharmacologic interventions, and helping patients cope with symptom distress. Mucositis can have a negative impact on the overall treatment experience, especially when severe pain or infections occur. Many interventions for managing mucositis exist; however, some are based in tradition or expert opinion and have not been studied in large, randomized, controlled trials. In addition, a variety of assessment tools are available, which creates confusion and difficulties when comparing interventions across studies. This article reviews empirical evidence related to interventions for oral mucositis. Oral care and rinses, pharmacologic interventions, and other techniques are evaluated. Gaps in the literature and opportunities for research, education, and practice changes are discussed.

show abstract

Section: Pilocarpinementioning

confidence: 99%

Putting Evidence Into Practice®: Evidence-Based Interventions for the Management of Oral Mucositis

Harris¹,

Eilers²,

Harriman³

et al. 2008

Clinical Journal of Oncology Nursing

107

View full text Add to dashboard Cite

show abstract

“…Als häufigste Schmerzursache während der antineo plastischen Therapie wird von betrof fenen Kindern, deren Eltern und Kinde ronkologen die therapiebedingte Muko sitis genannt [21,22,26,37]. Die chemo therapieassoziierte Mukositis tritt wäh rend bestimmter Behandlungsprotokolle regelmäßig und vorhersagbar auf [9]. Ih re Dauer und Schwere variieren von Pa tient zu Patient (in Abhängigkeit von den eingesetzten Chemotherapeutika, aber auch bei gleicher Behandlung) und durch unterschiedlich lange Pausen vor den Chemotherapiezyklen oder anderen Begleitumständen in geringerem Maße von Chemotherapiezyklus zu Chemo therapiezyklus beim gleichen Patienten [1,2].…”

Section: Zirkadianer Rhythmus Des Pca-gesteuerten Opioidverbrauchs Beunclassified

“…In den 3 verfügbaren pädiatrischen Stu dien erweist sich die PCA jedoch als ei [15,23]. Dies wird durch ei ne aktuelle CochraneAnalyse belegt und entspricht den Erkenntnissen zum opio idsparenden Effekt der PCA in der post operativen Schmerztherapie [9,20].…”

Section: Pca Zur Schmerztherapie Bei Mukositisunclassified

See 1 more Smart Citation

Zirkadianer Rhythmus des PCA-gesteuerten Opioidverbrauchs bei Kindern mit chemotherapiebedingter Mukositis

Schießl

Schestag

Grießinger

et al. 2008

Schmerz

View full text Add to dashboard Cite

PCA seems to be an ideal, dependable and feasible mode of analgesic administration for the individual titration of dose in children with chemotherapy-induced mucositis. This is expressed through the increase in daily self-administered opioid doses after starting PCA, the huge interindividual variability in opioid consumption and the rare event of an un-delivered bolus request during lock-out time. With the use of a background infusion, additional bolus requests are rare during the night.

show abstract

“…[5][6][7] Newer products: MuGard TM , Caphosol R and Episil R have been recently introduced. Given the radiotherapy treatment volume in SCCHN, the majority of the oral mucosa will receive a significant dose of radiation; OM is realistically an inevitable toxicity rather than preventable consequence of head and neck radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

The use of MuGard™, Caphosol^®and Episil^®in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck

et al. 2013

View full text Add to dashboard Cite

Introduction: Oral mucositis is common for patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN). Despite the significant detrimental sequelae associated, there is no consensus on the optimum mouth care regimen. This prospective audit aims to record mucositis and dysphagia toxicity and the level of analgesia prescribed when recent products: MuGard TM , Caphosol R and Episil R are compared with our standard departmental mouth care regimen.Methods: Patients undergoing concurrent chemoradiotherapy for locally advanced SCCHN at University Hospital Birmingham, UK were prospectively audited weekly for 8 consecutive weeks starting from week 1 of chemoradiotherapy from June 2009 until January 2011. Patients received either standard oral care regimen of aspirin, glycerin and sucralfate, or, MuGard TM , Caphosol R or Episil R . Grade of mucositis, dysphagia and analgesia score were prospectively recorded using the common toxicity criteria v3?0.Results: One hundred and four patients were included. There was no difference in the grade and duration of mucositis (p 5 0?82), dysphagia (p 5 0?99) or analgesia score (p 5 0?61) for either MuGard TM , Caphosol R or Episil R compared with standard oral care.Conclusion: There is no evidence from this audit that Mugard TM , Caphosol R or Episil R improves mucositis and dysphagia toxicity or the level of analgesia prescribed compared with our standard departmental mouth care regimen. Randomised trials comparing these approaches are required to detect any meaningful clinical benefit.

show abstract

Interventions for treating oral mucositis for patients with cancer receiving treatment

Cited by 31 publications

References 52 publications

Putting Evidence Into Practice®: Evidence-Based Interventions for the Management of Oral Mucositis

Putting Evidence Into Practice®: Evidence-Based Interventions for the Management of Oral Mucositis

Zirkadianer Rhythmus des PCA-gesteuerten Opioidverbrauchs bei Kindern mit chemotherapiebedingter Mukositis

The use of MuGard™, Caphosol^®and Episil^®in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck

Contact Info

Product

Resources

About

Interventions for treating oral mucositis for patients with cancer receiving treatment

Cited by 31 publications

References 52 publications

Putting Evidence Into Practice®: Evidence-Based Interventions for the Management of Oral Mucositis

Putting Evidence Into Practice®: Evidence-Based Interventions for the Management of Oral Mucositis

Zirkadianer Rhythmus des PCA-gesteuerten Opioidverbrauchs bei Kindern mit chemotherapiebedingter Mukositis

The use of MuGard™, Caphosol®and Episil®in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck

Contact Info

Product

Resources

About

The use of MuGard™, Caphosol^®and Episil^®in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck